Related Experiment Videos
The epidermal growth factor receptor as a target for therapy
1University of Oxford, Institute of Molecular Medicine, John Radcliffe Hospital, UK.
Summary
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.
Clinical cancer research : an official journal of the American Association for Cancer Research·2001
Hypoxia-inducible expression of tumor-associated carbonic anhydrases.
Cancer research·2001
The short form of the alternatively spliced flt-4 but not its ligand vascular endothelial growth factor C is related to lymph node metastasis in human breast cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research·2000
Epithelial cell plasticity in neoplasia.
Cancer cells (Cold Spring Harbor, N.Y. : 1989)·1991
Uptake of low-density lipoprotein by malignant cells--possible therapeutic applications.
Cancer cells (Cold Spring Harbor, N.Y. : 1989)·1991
JE/MCP-1: an early-response gene encodes a monocyte-specific cytokine.
Cancer cells (Cold Spring Harbor, N.Y. : 1989)·1991
A role for cholinesterases in tumorigenesis?
Cancer cells (Cold Spring Harbor, N.Y. : 1989)·1991
The soluble interleukin-2 receptor as a marker for human neoplasia and immune status.
Cancer cells (Cold Spring Harbor, N.Y. : 1989)·1991
New directions in cancer therapy based on aberrant expression of glycosphingolipids: anti-adhesion and ortho-signaling therapy.
Cancer cells (Cold Spring Harbor, N.Y. : 1989)·1991
Targeting CXCR2 in Nociceptive Sensory Neurons Offers Novel Therapeutic Potentials for Postoperative Pain.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Letter to "NR1D2 Knockdown Alleviates Myocardial Infarction Through Nrf2 Signaling Pathway Activation".
Cardiovascular drugs and therapy·2026
ERK1/2 Inhibitor Ulixertinib in Pan-cancer Patients with BRAF Fusions or Non-V600E/K Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1L.
Clinical cancer research : an official journal of the American Association for Cancer Research·2026